Overview
The effect of neoadjuvant chemotherapy for pancreatic cancer was gradually established. However it has been not clarified which regimen of neoadjuvant treatment for pancreatic cancer is the best.
Description
gemcitabine plus S-1 versus gemcitabine plus nab-paclitaxel
Eligibility
Inclusion Criteria:
elective pancreatectomy for pancreatic cancer
Exclusion Criteria:
a previous cancer surgery a body weight loss of >10% during the 6 months before surgery the presence of distant metastases seriously impaired function of vital organs because of respiratory, renal, or heart disease.